Proton Beam Therapy of Parapapillary Choroidal Melanoma

2014 ◽  
Vol 157 (6) ◽  
pp. 1258-1265 ◽  
Author(s):  
Aline I. Riechardt ◽  
Dino Cordini ◽  
Gregor D. Willerding ◽  
Inna Georgieva ◽  
Andreas Weber ◽  
...  
Author(s):  
E.C. Choi ◽  
J. Park ◽  
D. Shin ◽  
J.Y. Kim ◽  
J.H. Kim ◽  
...  

2017 ◽  
Vol 27 (5) ◽  
pp. 596-600 ◽  
Author(s):  
Ariane Malclès ◽  
Anh-Minh Nguyen ◽  
Thibaud Mathis ◽  
Jean-Daniel Grange ◽  
Laurent Kodjikian

Purpose To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). Methods Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile. Results Mean age was 55.6 years (range 34-85). Mean time between PBT and DEX-I was 12.4 months (range 3-25). Mean follow-up was 9.9 months (range 4-15). Intravitreal Ozurdex® reduced exudative RD in 7 cases (70%) on average 3.1 months after injection with complete resolution of RD in 6 of these (60%). For half of the patients, their level of vision remained stable; the other half experienced a deterioration in visual acuity at the end of follow-up. No adverse effects were observed. Conclusions In this small case series, treatment with intravitreal DEX-I reduced exudative RD in the majority of cases and had an acceptable safety profile.


2016 ◽  
Vol 07 (03) ◽  
pp. 169-185 ◽  
Author(s):  
Victoria L. Tseng ◽  
Anne L. Coleman ◽  
Zuo-Feng Zhang ◽  
Tara A. McCannel

2017 ◽  
Vol 255 (11) ◽  
pp. 2263-2269 ◽  
Author(s):  
Aline I. Riechardt ◽  
Daniel Pilger ◽  
Dino Cordini ◽  
Ira Seibel ◽  
Enken Gundlach ◽  
...  

2015 ◽  
Vol 22 (6) ◽  
pp. 1036-1037 ◽  
Author(s):  
Claudia Scaringi ◽  
Giuseppe Minniti ◽  
Alessandro Bozzao ◽  
Felice Giangaspero ◽  
Teresa Falco ◽  
...  

Eye ◽  
2015 ◽  
Vol 29 (9) ◽  
pp. 1194-1198 ◽  
Author(s):  
M J Sikuade ◽  
S Salvi ◽  
P A Rundle ◽  
D G Errington ◽  
A Kacperek ◽  
...  

2021 ◽  
pp. 112067212110673
Author(s):  
Louis Marin ◽  
Elsa Toumi ◽  
Jean-Pierre Caujolle ◽  
Jérôme Doyen ◽  
Arnaud Martel ◽  
...  

Purpose Radiation maculopathy (RM) is the leading cause of visual acuity (VA) loss after proton beam therapy (PBT) of choroidal melanoma. The aim of this study was to assess the value of optical coherence tomography-angiography (OCT-A) for the diagnosis of RM in patients with choroidal melanoma treated with PBT. Materials & methods This 2-year prospective, descriptive, single-center study included patients treated with PBT for choroidal melanoma. VA measurement, retinography, OCT and OCT-A were performed. Vascular density (VD) in the superficial capillary plexus (SCP), peri-foveal anastomotic ring changes and foveal avascular zone (FAZ) enlargement were studied. Results Nineteen patients were included in the study. The median baseline melanoma thickness was 5.7 [3.6–8.1] mm. The median melanoma-to-macula distance was 3.5 [2.6–4.6] mm. The earliest signs of RM identified on retinography were hard exudates developing at 12 [12–24] months, followed by retinal hemorrhages at 18 [12–30] months, found in 88.9% and 77.8% of patients respectively. On OCT, the earliest sign was the onset/progression of cystoid macular edema (CME) at 12 [6–12] months, found in 10 patients (52.6%). On OCT-A, 100% of patients presented with a discontinuity of the perifoveal anastomotic ring and a FAZ enlargement after 12 [6–24] months. After 12 months, a VD loss in the SCP by 11.7% and 10.8% compared to baseline, was found in the macular and foveal areas respectively. A significant negative correlation was found between the VA and the VD in the macular SCP (R = −0.43; p = 0.029). Conclusion OCT-A is a reliable and effective diagnostic tool for RM in patients with choroidal melanoma treated with PBT.


Sign in / Sign up

Export Citation Format

Share Document